❯ Isomorphic Labs discusses about $5 billion in funding at a roughly $50 billion valuation while drug programs remain preclinical

A funding amount emerges this weekIsomorphic Labs is discussing roughly $5 billion in new funding at a valuation of about $50 billion, Bloomberg reported on November 4. Earlier discussions had already indicated a potential new valuation; this week’s report adds the proposed amount. The financing has not closed and terms could change. The company did not respond to a request for comment.

Using models to design medicinesFormed out of Google DeepMind in 2021, Isomorphic built on the research behind the AlphaFold protein-structure model to develop its AI drug design engine, IsoDDE. Its business includes wholly owned drug candidates and partnered programs with companies including Novartis, Lilly and Johnson & Johnson. Partners obtain drug discovery and design capabilities, while internal programs allow Isomorphic to retain more of the potential rights in future medicines.

A completed round in MayThe company announced a $2.1 billion Series B on May 12, led by Thrive Capital with participation from Alphabet, GV and others. Those proceeds were intended to scale its design engine, advance candidates toward the clinic and hire AI, drug design and clinical specialists. That completed financing is separate from the approximately $5 billion now being discussed.

Clinical validation lies aheadAt the Bloomberg Tech conference on Monday this week, president Max Jaderberg said the company’s work remained preclinical and that the business was still in its early innings. Chief executive Demis Hassabis had said earlier in the year that he expected the first clinical trials by the end of 2026; that goal has not yet become an achieved milestone. Allocation of the proposed new funds has not been announced, and designed candidates still require experimental, clinical and subsequent development work to establish medical and commercial value.

▮ SIGNALIsomorphic’s valuation anticipates a platform that can repeatedly generate drug candidates, while its programs remain preclinical; investors are pricing that repeatability before clinical results can test whether it survives the later stages of drug development.